3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Unknown
1
Recruiting
1
Completed
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gastrointestinal
1
Dermatologic
1
Conditions
Breast Neoplasms
51
Neoplasms
34
Colorectal Neoplasms
23
Lung Neoplasms
17
Prostatic Neoplasms
16
Melanoma
15
Neoplastic Cells, Circulating
13
Pancreatic Neoplasms
11
Multiple Myeloma
11
Uterine Cervical Neoplasms
10
Ovarian Neoplasms
10
Carcinoma, Non-Small-Cell Lung
8
Papillomavirus Infections
7
Neoplasm Metastasis
7
Leukemia, Myeloid, Acute
7
Colonic Neoplasms
7
Lymphoma, Follicular
6
Lymphoma
6
Hematologic Neoplasms
6
Uveal Melanoma
5
Sarcoma
5
Head and Neck Neoplasms
5
Glioma
5
Uterine Cervical Dysplasia
4
Urinary Bladder Neoplasms
4
Rectal Neoplasms
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Glioblastoma
4
Disease
4
COVID-19
4
Interventions
Imatinib Mesylate
41
Sunitinib
17
nilotinib
12
regorafenib
10
ripretinib
6
avapritinib
6
Leucovorin
3
Ipilimumab
3
Gemcitabine
3
Dasatinib
3
CTLA-4 Antigen
3
4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one
3
pexidartinib
2
Paclitaxel
2
Oxaliplatin
2
Midazolam
2
Irinotecan
2
Fluorouracil
2
Floxuridine
2
Erlotinib Hydrochloride
2
Docetaxel
2
Cisplatin
2
Carboplatin
2
Capecitabine
2
Biopsy, Fine-Needle
2
Bevacizumab
2
vatalanib
1
umbralisib
1
trametinib
1
tinostamustine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Gastrointestinal Stromal Tumors
×
Blood Specimen Collection
×
Clear all
NCT01046487
2026-03-13
PALANGI3
Centre Oscar Lambret
Phase 1
Completed
26 enrolled